| Grant ID | RP240119 |
| Awarded On | February 21, 2024 |
| Title | Integrating proteolysis-targeting capability into antibodies to augment therapeutic efficacy |
| Program | Academic Research |
| Award Mechanism | Individual Investigator |
| Institution/Organization | The University of Texas Health Science Center at Houston |
| Principal Investigator/Program Director | Qingyun Liu |
| Cancer Sites | Colorectal, Lung and Bronchus |
| Contracted Amount |
$1,050,000* *Pending contract negotiation |
| Lay Summary |
The goa of this project is to make current cancer treatment drugs work better by enabling the drugs to attack cancer cells more effectively. Antibodies are some of the most successful classes of cancer drugs, including those used in immune therapy. Nearly all antibody drugs work by blocking the function of genes that drive cancer growth or spread or both. Unfortunately, the antibodies may not be able to completely block the cancer gene's function and cancer genes can mutate to escape from the antibody, leading to drug resistance and eventually cancer relapse. We found that if we tag the antibodies with a molecule that is able to induce protein degradation, the antibodies become more eff... |